Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
The American Medical Association (AMA) has added two new Current Procedural Terminology (CPT) codes for reporting antigen tests that detect both COVID-19 and influenza.
Effective immediately, the new Category I CPT codes are 87636 and 87637.
|
Long Code Descriptor |
Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique |
|
Medium Code Descriptor |
IADNA SARSCOV2 & INF A&B MULT AMPLIFIED PROBE TQ |
|
Short Code Descriptor |
SARSCOV2 & INF A&B AMP PRB |
|
Long Code Descriptor |
Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique |
|
Medium Code Descriptor |
IADNA SARSCOV2 & INF A&B & RSV MULT AMP PROBE TQ |
|
Short Code Descriptor |
SARSCOV2 & INF A&B&RSV AMP PRB |
These new codes “report nucleic acid assays that allow a single test to simultaneously detect the novel coronavirus and a combination of common viral infectious agents, including influenza A/B and respiratory syncytial virus,” AMA president Susan Bailey explained on 7 October. “Concurrent detection promises to conserve important testing resources, allowing for ongoing surveillance of influenza while testing for the novel coronavirus.”
Meanwhile, the AMA added a third new Category I code, 87811, for reporting “infectious agent antigen detection by immunoassay with direct visual observation.”
|
Long Code Descriptor |
Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) |
|
Medium Code Descriptor |
IAADIADOO SEVERE AQT RESPIR SYND CORONAVIRUS |
|
Short Code Descriptor |
SARS-COV-2 COVID19 W/OPTIC |
The AMA says other recent changes to the CPT code set in relation to COVID-19 can be found on the group’s website.
Medtech Insight: global medical technology news & analysis
By Amanda Maxwell 05 Aug 2021
The performance of COVID-19 tests circulating on the EU market has been harshly criticized. With the EU’s IVD Regulation still...
Medtech Insight: global medical technology news & analysis
By Amanda Maxwell 04 Aug 2021
The medtech industry needs to keep alert; the publication of documents related to and supporting the implementation of the Medical...
Medtech Insight: global medical technology news & analysis
04 Aug 2021
US Medicare’s designation of Boston Scientific’s single-use duodenoscope aims to reduce infections from a popular procedure to treat pancreatic and...
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
In the continually evolving medtech competitive landscape, it is vital to stay up-to-date with key events. With Meddevicetracker, you’ll be able to anticipate upcoming filings, research clinical trial dates and data, and access market size information and expert forecasts, all in one place.
Get a window into what the leading players across the biopharma, medtech, and diagnostics industries are thinking, as well as important insight into what your competitors are doing. Build your strategy with In Vivo.
Looking for more products Product Finder
